Newer thrombolytic agents

Annals of the Academy of Medicine Singapore

Volumn 28, Issue 3, 1999, Pages 424-433

  Verstraete, Marc ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Monteplase; Pro urokinase; Reteplase; Saruplase; Staphylokinase; TNK t PA; YM866

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; LANOTEPLASE; MONTEPLASE; PALMITEPLASE; PAMITEPLASE; PROLYSE; RECOMBINANT GLYCOSYLATED PROUROKINASE; RESCUEPLASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0032881338     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, et al. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991; 17:738-46.
2. Kawai C, Hosoda S, Kimata S, Karimatsuse K, Suzuki S, Motomiya T, et al. Coronary thrombolysis in acute myocardial infarction of E6010 (Novel modified t-PA): A multicenter, double-blind, dose-finding study. Jpn Pharmacol Ther 1994; 22:3925-50 (in Japanese).
3. Kawai C, Yui Y, Hosoda S, Nobuyoshi M, Suzuki S, Sato H, et al on behalf of the E6010 Study Group. A prospective, randomized, double-blind multicenter trial of single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native tPA. J Am Coll Cardiol 1997; 29:1447-53.
4. Refino C J, Paoni N F, Keyt B A, Pater C S, Badillo J M P, Wurm F M, et al. A variant of t-PA (T103N, KHRR296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993; 70:313-9.
5. Keyt B, Paoni N F, Refino C J, Berleau L, Nguyen L, Chow A, et al. A fasteracting and more potent form of tissue plasininogen activator. Proc Natl Acad Sci USA 1994; 91:3670-4.
6. Collen D, Stassen J M, Yasuda T, Refino C, Paoni N, Keyt B, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72:98-104.
7. Fay W P, Eitzman D T, Shapiro A D, Madison E L, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood 1994; 83:351-6.
8. Cannon C P, McCabe C H, Gibson C M, Ghali M, Seqeira R F, McKendall G R, et al and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95:351-6.
9. Cannon C P, Gibson C M, McCabe C H, Adgey A A J, Schweiger M J, Sequieira R F, et al for the TIMI 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998; 98:2805-14.
10. Gingliano R P, Cannon C P, McCabe C H, Van de Werf F, Braunwald E. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorhage: Results from TIMI 10B and Assent 1 [abstract]. Circulation 1997; 96:535.
11. Kohnert U, Rudolph R, Verheijen J H, Weening-Verhoeff E J D, Stem A, Opitz U, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Prot Eng 1992; 5:93-100.
12. St ürzebecher J, Neumann U, Kohnert U, Kresse G B, Fischer S. Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Prot Sci 1992; 1:1007-13.
13. Hajjar K A. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991; 266:21962-70.
14. Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, et al. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991; 65:560-4.
15. Martin U, von Molendorff E, Akpan W, Kientsch Engel R, Kaufmann B, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50:429-36.
16. Müller M, Havrer W, Ellbruck D, Martin U, Konig R, Seifried E for the GRECO Study Group. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients [abstract]. Fibrinolysis 1992; 6(Suppl 2):26.
17. Neuhaus K L, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner H J, et al. Dose-finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994; 24:55-60.
18. Tebbe U, von Essen R, Smolarz A, Limbour G P, Rox J, Rustige J, et al. Open, non-controlled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993; 72:518-24.
19. Bode C, Smalling R W, Berg G, Burnett C, Lorch G, Kalbfleisch J M, et al for the Rapid II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94:891-8.
20. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison to reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346:329-36.
21. The global use of Strategies to open occluded coronary arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:118-23.
22. Lau D, Kuzma G, Wei C M, Livingston D J, Hsiung N. A modified human tissue plasminogen activator with extended half-life in vivo. Biol Tech 1987; 55:953-8.
23. Larsen G R, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73:1842-50.
24. Eidt J F, McNatt J, Wydro R M, Yao S K, Allison P, Garramone S, et al. Coronary thrombolysis with a variant of human tissue-type plasminogen activator in a canine preparation: slightly enhanced thrombolysis and prolonged time to reocclusion. Coron Artery Dis 1991; 2:931-40.
25. Liao W C, Beierle F A, Stouffer B C, Dockens R A, Abbud Z A, Tay L K, et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: pharmacokinetic evaluation from InTIME-I study [abstract]. Circulation 1997; 96(Suppl 1):I-260-I-261.
26. White H D, Van de Werf F J. Thrombolysis for acute myocardial infarction. Ciruclation 1998; 97:1632-46.
27. Katoh M, Suzuki Y, Miyamoto I, Watanabe T, Mori K, Arakawa H, et al. Biochemical and pharmacokinetic properties of YM866, a novel fibrinolytic agent [abstract]. Thromb Haemost 1991; 65:1193.
28. Oikawa Y, Kamimura H, Watanabe T, Miyamoto I, Higuchi S. Metabolic fate of YM866, a novel fibrinolytic agent [1]: plasma concentration, distribution, metabolism and excretion in rats after single intravenous administration. Xenobiometab and Dispos 1996; 11:1-10.
29. Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, et al. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. JpnJ Pharmacol 1993; 63:9-16.
30. Hashimoto K, Oikawa K, Miyamoto I, Hayamizu K, Abe Y. Phase I study of a novel modified t-PA. Jpn J Med Pharm Sci 1996; 36:623-46.
31. Haze K, Kawai C, Hosoda S, Aoki N, Takano T, Kammatsuse K, et al. Efficacy and safety of intra-coronary administration of YM866 (modified tissue-type plasminogen activator) in patients with acute myocardial infarction. Jpn Pharmacol Ther 1996; 24:2468-990.
32. Yui Y, Haze K, Kawai C, Hosoda S, Aoki N, Takano T, et al. Randomized, double-blind multicenter trial of YM866 (modified t-PA) by intravenous bolus injection in patients with acute myocardial infarction in comparison with tisokinase (native t-PA). J N Remedies Clin 1996; 45:2175-221.
33. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1:863-7.
34. Vermeer F, Bär F, Windeler J, Riedel A. Saruplase, a new fibrin specific thrombolytic agent. Results of one year follow-up in the PASS study (1698 patients) [abstract]. Ann Haematol 1994; 69:66.
35. Kentzer E J, Buko A M, Menon G, Sarin V K. Carbohydrate composition and presence of a fucose protein linkage in recombinant human pro-urokinase [abstract]. Biochim Biophys Res Comm 1990; 171:401.
36. Lenich C, Pannell R, Henkin J, Gurewich V. The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. Thromb Haemost 1992; 68:539-44.
37. Credo R B, Burke S E, Barker W M, Villiard E M, Sweeny J M, Henkin J, et al. Recombinant glycosylated prourokinase: biochemistry, pharmacology, and early clinical experience. In: Sasahara A A, Loscalzo J, editors. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker Inc, 1997:561-90.
38. Weaver W D, Hartmann J R, Anderson J L, Reddy P S, Sobolski J C, Sasahara A A. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24:1242-8.
39. Lack C H. Staphylokinase: an activator of plasma protease. Nature 1948; 161:559-60.
40. Lewis J H, Ferguson J H. A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase. Am J Physiol 1951; 166:594-603.
41. Winkler K C, DeWaart J, Grootsen C, Zegers B J M, Tellier N F, Verlegt C D. Lysogenic conversion of staphylococci to loss of beta-toxin. J Gen Microbiol 1965; 39:321-33.
42. Collen D, Silence K, Demarsin E, De Mol M, Lijnen H R. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6:203-13.
43. Sako T, Tsuchida N. Nucleotide sequence of the staphylokinase gene from Staphylococcus aureus. Nucleic Acids Res 1983; 11:7679-93.
44. Behnke D, Gerlach D. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase - a bacterial plasminogen activator. Mol Gen Genet 1987; 210:528-34.
45. Collen D, Zhao Z A, Holvoet P, Marynen P. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992; 6:226-31.
46. Sako T. Overproduction of staphylokinase in Escherichia coli and characterization. Eur J Biochem 1985; 149:557-63.
47. Gerlach D, Kraft R, Behnke D. Purification and characterization of the bacterial plasminogen activator staphylokinase secreted by a recombinant Bacillus subtilis. Zentralbl Bakteriol Mikrobiol Hyg A 1988; 269:314-22.
48. Kowalska-Loth B, Zakrzewski K. The activation by staphylokinase of human plasminogen. Acta Biochim Pol 1975; 22:327-39.
49. Lijnen H R, Van Hoef B, Collen D. Interaction of staphylokinase with different molecular forms of plasminogen. Eur J Biochem 1993; 211:91-7.
50. Lijnen H R, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. Biol Chem 1991; 266:11826-32.
51. Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen H R, et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 1993; 268:8284-9.
52. Reddy K N, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. J Biol Chem 1972; 247:1683-91.
53. Silence K, Hartmann M, Guhrs K H, Gase A, Schlott B, Collen D. Structurefunction relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis. J Biol Chem 1995; 270:27192-8.
54. Sakharov D V, Lijnen H R, Rijken DC. Interactions between staphylokinase, plasmin(ogen) and fibrin: staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271:27912-8.
55. Collen D, Lijnen H R. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84:680-6.
56. Lijnen H R, Collen D. Staphylokinase, a fibrin-specific bacterial plasminogen activator. Fibrinolysis 1996; 10:119-26.
57. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87:1850-3.
58. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolic M, et al for the STAR Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92:2044-9.
59. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92:2050-7.
60. Vanderschueren S, Collen D, Van de Werf F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis. Thromb Haemost 1996; 76:541-4.